Blog Posts

BIG PHARMA WATCH: MERCK TAKES ANOTHER STEP TOWARD FURTHER EXTENDING PATENT EXCLUSIVITY ON BLOCKBUSTER CANCER DRUG KEYTRUDA

Nov 25, 2024

Big Pharma Giant Proceeds With Strategy to Block Competition, Add More Patents Read More

CSRxP STATEMENT ON SENATE JUDICIARY MARKUP OF THE PREVAIL ACT

Nov 21, 2024

Congress Should Not Further Consider Misguided Proposal That Would Enable More Read More

CSRxP ANALYSIS FINDS PHARMACEUTICAL INDUSTRY’S PROFIT MARGINS TEN TIMES GREATER THAN OTHER SECTORS OF DRUG SUPPLY CHAIN

Nov 20, 2024

Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels Read More

BIG PHARMA WATCH: NOVO NORDISK LAUNCHES WEGOVY IN CHINA AT 85 PERCENT DISCOUNT COMPARED TO U.S.

Nov 19, 2024

Brand Name Manufacturers Continue to Charge U.S. Patients Highest Prices in Read More

BIG PHARMA WATCH: BRAND NAME DRUG MAKER TOUTS PATENT ABUSE PLAYBOOK THAT DELAYED ACCESS TO SAFER AND MORE EFFECTIVE TREATMENTS

Nov 15, 2024

Gilead CEO Touts Success of Company’s Patent Playbook on HIV Portfolio That Read More

BIG PHARMA EARNINGS WATCH: BRISTOL MYERS SQUIBB AND MERCK

Nov 11, 2024

Big Pharma Giants Conclude Latest Round of Earnings Reports Fueled by Read More

BIG PHARMA EARNINGS WATCH: NOVARTIS AND PFIZER

Nov 8, 2024

Big Pharma Giants Keep Beating Wall Street Expectations While Continuing to Read More

BIG PHARMA EARNINGS WATCH: ABBVIE, AMGEN AND GSK

Nov 7, 2024

Big Pharma Giants Rolling in Strong Earnings While Continuing to Hike Drug Read More

BIG PHARMA EARNINGS WATCH: ROCHE AND SANOFI

Oct 28, 2024

Big Pharma Giants Continue Reporting Expectation-Beating Q3 Earnings After Read More

SECOND OPINION: BIG PHARMA ONCE AGAIN TRIES TO DEFEND THE PATENT ABUSE STATUS QUO

Oct 23, 2024

Eli Lilly Opinion Column Reiterates Debunked Arguments on Innovation as Brand Read More

BIG PHARMA EARNINGS: JOHNSON & JOHNSON

Oct 17, 2024

Johnson & Johnson Reports Higher-Than-Expected Earnings Fueled by Price Read More